Welcome to our dedicated page for Zoetis SEC filings (Ticker: ZTS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Zoetis Inc. (ZTS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Zoetis, described as the world’s leading animal health company, uses filings such as Form 8-K to report material events related to its operations, financing activities, governance and shareholder returns.
Recent 8-K filings detail several types of information. Zoetis has reported the completion of a private offering of 0.25% Convertible Senior Notes due 2029, including the terms of the notes, their conversion features, optional redemption provisions and related capped call transactions. Other filings describe the issuance of senior notes due 2028 and 2035 under an existing indenture, as well as a revolving credit agreement that provides a senior unsecured revolving credit facility and replaces a prior credit agreement.
Filings also cover corporate actions affecting shareholders, such as declarations of cash dividends on Zoetis common stock and the use of proceeds from financing transactions to repurchase shares under an existing share repurchase program. Additional 8-Ks report quarterly financial results, guidance updates, and investor presentations, including an Innovation Webcast that outlines the company’s pipeline and strategic approach to addressing unmet medical needs in animals.
Through this page, users can review how Zoetis discloses information about its NYSE-listed common stock, debt obligations, credit facilities and board-level decisions. Stock Titan’s platform associates these filings with AI-powered tools that summarize key terms and highlight items such as note covenants, leverage provisions, dividend declarations and event-driven disclosures, helping readers interpret lengthy documents more efficiently.
Hattersley Gavin reported acquisition or exercise transactions in this Form 4 filing.
Zoetis Inc. director Gavin Hattersley reported an equity award of 1,936 restricted stock units (RSUs) on February 18, 2026 at a stated price of $0.00 per unit, reflecting a grant under the company’s Amended and Restated 2013 Equity and Incentive Plan.
Each RSU represents a contingent right to receive one share of Zoetis common stock and will vest and be settled on the first anniversary of the grant date, February 18, 2026, subject to his continued service and certain earlier vesting conditions. Following these transactions, Hattersley directly holds RSUs including 1,619.3325 units from a prior grant scheduled to vest on February 19, 2025.
Driscoll Rimma reported acquisition or exercise transactions in this Form 4 filing.
Zoetis Inc. Executive Vice President Rimma Driscoll reported equity awards under the company’s Amended and Restated 2013 Equity and Incentive Plan. On February 18, 2026, she received 2,323 restricted stock units (RSUs) and 9,191 stock options, each RSU representing one share of common stock.
One-third of the new RSUs and one-third of the options vest on each of the first, second and third anniversaries of the grant date, subject to continued service and certain earlier‑vesting events. Each option allows her to buy Zoetis common stock and expires on the tenth anniversary of its grant.
PECK KRISTIN C reported acquisition or exercise transactions in this Form 4 filing.
Zoetis Inc. reported that Chief Executive Officer Kristin C. Peck received new equity awards. On February 18, 2026, she was granted 28,072 restricted stock units (RSUs) and 111,060 stock options at no cost, as compensation awards.
Each RSU represents a contingent right to one share of Zoetis common stock and, according to the plan terms, one-third of each RSU and one-third of each option will vest on the first, second, and third anniversaries of the February 18, 2026 grant date, subject to continued service and certain earlier vesting events. The options expire on the tenth anniversary of the grant date.
Ashton Nicholas reported acquisition or exercise transactions in this Form 4 filing.
Zoetis Inc. Executive Vice President Nicholas Ashton reported equity awards consisting of restricted stock units (RSUs) and stock options. On February 18, 2026, he received a grant of 4,148 RSUs and 16,413 stock options under the Zoetis Amended and Restated 2013 Equity and Incentive Plan.
Each RSU represents a contingent right to receive one share of Zoetis common stock. One-third of each RSU and one-third of each option vest on the first, second and third anniversaries of the grant date, subject to his continued service and certain earlier vesting events. Each option expires on the tenth anniversary of its grant date.
Zoetis Inc. Executive Vice President Jamie Brannan received new equity awards. On February 18, 2026, Brannan was granted 5,399 restricted stock units and 21,361 stock options, each at an exercise price of $0.00 per unit or option.
Each RSU represents a contingent right to receive one share of Zoetis common stock. One-third of the RSUs and one-third of the options will vest on each of the first, second and third anniversaries of the grant date, subject to continued service and certain earlier-vesting events. Following these grants, Brannan directly holds RSUs and multiple option positions reflecting prior annual awards under the company’s equity and incentive plans.
Joseph Wetteny reported acquisition or exercise transactions in this Form 4 filing.
Zoetis Inc. Chief Financial Officer Joseph Wetteny reported new equity awards and updated holdings. On February 18, 2026 he received grants of 8,605 restricted stock units and 34,045 stock options at a price of $0.00 per share, vesting in three annual installments, alongside disclosures of existing option and RSU positions.
Zoetis Inc. Chief Executive Officer Kristin C. Peck reported exercising stock options for 20,000 shares of Zoetis common stock at an exercise price of $41.83 per share on February 17, 2026. On the same day, she completed preplanned open‑market sales totaling 20,000 shares under a Rule 10b5‑1 trading plan.
The sales were split into 9,200 shares at a weighted average price of $126.4601 (with individual trades ranging from $126.01 to $126.98) and 10,800 shares at a weighted average price of $127.5492 (with trades from $127.01 to $127.56). Following these transactions, she directly held 101,337 shares of common stock and indirectly held 833.6435 common stock equivalents through the Zoetis 401(k) savings plan as of December 31, 2025, along with substantial remaining stock options.
Zoetis Inc. insider plans Rule 144 sale of common stock. A filing indicates an intention to sell 2,346 shares of Zoetis common stock through Merrill Lynch on the NYSE, with an aggregate market value of $298,741.99 and 422,127,709 shares outstanding.
The shares come from equity compensation, including vested restricted stock units and performance share awards granted under the issuer’s equity compensation plan. The seller, identified as Robert Polzer, previously sold 3,662 shares of common stock in the past three months for gross proceeds of $472,727.58.
Zoetis Inc. insider plans Rule 144 sale of common stock. A holder has filed to sell 20,000 shares of Zoetis common stock through Merrill Lynch on the NYSE, with an aggregate market value of $2,540,963.98 and 422,127,709 Zoetis shares outstanding.
The shares were acquired on 02/17/2026 by exercising employee stock options in a broker-assisted cashless exercise, and the approximate sale date listed is also 02/17/2026. The filer represents they are not aware of any undisclosed material adverse information about Zoetis.
Zoetis Inc. insider plans to sell common stock under Rule 144. A person associated with Zoetis filed a notice to sell 3,662 shares of Zoetis common stock through Merrill Lynch on or about 02/13/2026 on the NYSE, with an aggregate market value of $472,727.58.
The filing shows these shares were accumulated mainly through vesting of restricted stock unit and performance share awards, plus an employee stock option exercise between 2022 and 2025. Zoetis had 422,127,709 common shares outstanding when the notice was prepared.